Cormorant Asset Management, LP Aerovate Therapeutics, Inc. Transaction History

Cormorant Asset Management, LP

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.68 - $29.57 $2.51 Million - $4.2 Million	-141,900 Reduced 11.71%	1,069,796 $31.6 Million
Q4 2023 Feb 14, 2024	SELL	$9.58 - $24.25 $3.35 Million - $8.49 Million	-350,000 Reduced 22.41%	1,211,696 $27.4 Million
Q1 2023 May 15, 2023	SELL	$19.17 - $27.7 $7.58 Million - $11 Million	-395,436 Reduced 20.2%	1,561,696 $31.5 Million
Q4 2022 Feb 14, 2023	SELL	$15.92 - $30.52 $5.95 Million - $11.4 Million	-373,559 Reduced 16.03%	1,957,132 $57.3 Million
Q3 2022 Nov 14, 2022	BUY	$14.77 - $25.79 $8.86 Million - $15.5 Million	600,000 Added 34.67%	2,330,691 $38.6 Million
Q2 2022 Aug 15, 2022	SELL	$10.8 - $16.91 $1.08 Million - $1.69 Million	-100,000 Reduced 5.46%	1,730,691 $27.1 Million
Q4 2021 Feb 14, 2022	SELL	$9.14 - $21.54 $1.83 Million - $4.31 Million	-200,000 Reduced 9.85%	1,830,691 $21.6 Million
Q2 2021 Aug 16, 2021	BUY	$22.83 - $22.83 $46.4 Million - $46.4 Million	2,030,691 New	2,030,691 $44.6 Million

28.1M

116K

26.6K

Ticker AVTE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,448,100
Market Cap $61.9M
Description
Aerovate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. The company focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which ...

Get notified when there are updates to the investment portfolio of Cormorant Asset Management, LP, based on Form 13F filings with the SEC.

Stay updated on Cormorant Asset Management, LP with notifications on news.